Furthermore, the use of MEK inhibitors/PARPi combination or MEK inhibitors/PARPi/anti-PD-L1 triple therapy in BRCA wild-type tumor patients in NCT03695380 has demonstrated overall ORR and PFS superiority over single-agent Rucaparib (204, 205). Here, MAP2K7 is linked to neoplasm.